Banna, G., Cortellini, A., Cortinovis, D., Tiseo, M., Aerts, J., Barbieri, F., . . . Addeo, A. (2021). Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): A prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]. ESMO Open.
Citação norma ChicagoBanna, G.L., et al. "Corrigendum to ‘The Lung Immuno-oncology Prognostic Score (LIPS-3): A Prognostic Classification of Patients Receiving First-line Pembrolizumab for PD-L1 ≥ 50% Advanced Non-small-cell Lung Cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]." ESMO Open 2021.
Citação norma MLABanna, G.L., et al. "Corrigendum to ‘The Lung Immuno-oncology Prognostic Score (LIPS-3): A Prognostic Classification of Patients Receiving First-line Pembrolizumab for PD-L1 ≥ 50% Advanced Non-small-cell Lung Cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]." ESMO Open 2021.